Clinical trial

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

NCT02253394

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-09-01

PhasePHASE4

Study timeline

Study start (actual)2015-09-01Date precision: month

Registry last updated2019-11-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Pulmonary Arterial Hypertensionunresolved

Interventions

Ambrisentan plus SpironolactoneDRUG

Ambrisentan plus PlaceboDRUG

Sponsors & collaborators

Brigham and Women's Hospitallead sponsor

Gilead Sciencescollaborator

Mapped research locations

BostonMassachusetts, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02253394 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.